Terbin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Terbin

Property Description
Active ingredient Terbinafine Hydrochloride
Form Oral tablets, Topical preparations (cream, solution, spray)
Pharmacological class Allylamine Antifungal Agent
Common purpose Elimination of fungal infections (fungicidal action)
Origin Synthetic compound

What Type of Medicine is Terbin?

Terbin is a brand-specific medicinal entity containing Terbinafine Hydrochloride, a synthetic, broad-spectrum antifungal agent. Pharmacologically, it belongs to the allylamine antifungal class, recognized globally for its high efficacy against dermatophytes. This classification is important because it confirms the drug's specialized nature: it is clinically recognized for its targeted action against the common fungi responsible for conditions like athlete's foot and nail infections. Terbin is typically positioned for both prescription and over-the-counter (OTC) use, depending on the formulation and country-specific regulatory status, ensuring accessibility for various fungal issues.

Composition and Available Forms of Terbin

The composition of Terbin centers solely on Terbinafine Hydrochloride, which is formulated into two main categories of preparation for distinct uses. For systemic therapy, Terbin is available as oral tablets, designed to address deeper or widespread infections by distributing the compound throughout the body. Conversely, for localized skin infections, it is prepared as various topical preparations—including creams, solutions, and sprays—where the active ingredient is suspended in a dermatologically suitable base. Both oral and topical formulations of Terbinafine are utilized for the management of fungal diseases.

Terbinafine's General Principle of Action

The fundamental principle behind Terbinafine's utility is its powerful fungicidal action, a property that is highly valued in pharmacological studies compared to mere growth inhibition. It achieves this by disrupting a critical enzyme necessary for the fungus to synthesize ergosterol, which is vital for maintaining its protective cell membrane. By blocking this process, Terbinafine destroys the cell's integrity and leads to the pathogen's death. This established mechanism ensures that the overall general purpose of Terbin is the definitive clearance of the fungal pathogen at a cellular level.

What side effects are possible with Terbin?

Possible Side Effects and Safety Information

The safety profile for oral Terbinafine (Terbin) is officially documented by government regulatory authorities, classifying adverse reactions by frequency and affected system-organ-class.


Key Adverse Reaction Classifications

The most commonly documented adverse reactions, classified as Very Common or Common in regulatory materials, typically involve the Gastrointestinal System (e.g., diarrhea, dyspepsia, nausea, abdominal pain), the Nervous System (e.g., headache), and Skin and Subcutaneous Tissue Disorders (e.g., rash, pruritus). Other common effects include Musculoskeletal issues like arthralgia and myalgia, and transient elevations of liver enzymes.

Clinically Significant and Rare Adverse Reactions

The official safety information highlights the risk of Rare or Very Rare but clinically severe adverse events, particularly concerning the Hepatobiliary Disorders and Blood and Lymphatic System Disorders. These include documented cases of serious liver injury, such as hepatic failure (sometimes fatal or requiring liver transplant), and severe hematologic disorders, such as neutropenia or agranulocytosis.

Very rarely, severe cutaneous reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported in postmarketing experience. Disturbances of taste and smell (dysgeusia, anosmia) are also documented, with the official label noting that these may be prolonged or permanent even after treatment cessation.


Official Safety Restrictions

The medicine is contraindicated in patients with pre-existing chronic or active liver disease, as this is a major constraint defined by the regulatory label. Use is not recommended for individuals with significant renal impairment (e.g., Creatinine Clearance le 50 mL/min). Furthermore, regulatory guidelines recommend liver function monitoring before starting treatment and periodically throughout the course, and mandate discontinuation if clinical or laboratory signs of liver injury or a progressive rash develop.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents describe the clinical profile and necessary actions in the event of an overdose with Terbin (terbinafine). Overdosage experience is limited, with only a few cases reported at single doses up to 5 grams.

Overdose Presentation and Symptoms
Nausea, vomiting, abdominal pain, dizziness, headache, rash, and frequent urination are the symptoms reported in cases of overdosage. These manifestations primarily affect the gastrointestinal, central nervous, and genitourinary systems.

Emergency Response and Required Actions

If an overdose is suspected, you must seek emergency medical attention immediately or call a poison help line.

Treatment for overdosage, as officially recommended, focuses on eliminating the drug from the system, primarily through the administration of activated charcoal. Medical management also involves providing symptomatic supportive therapy to address any of the reported clinical effects.

The practical implication of this guidance is that due to the risk of systemic effects, any known or suspected accidental or intentional ingestion above the therapeutic dose requires immediate professional medical evaluation to begin supportive care and drug elimination procedures.

Therapeutic Uses of Terbin

The medication is used to manage infections caused by fungus. It is generally applied across domains where additional symptomatic support is needed to help manage fungal symptoms and ease patient discomfort. The medication is commonly used to help with conditions presenting with systemic or localized discomfort that involve Onychomycosis (fungal nail infection), Tinea capitis (scalp ringworm), and extensive dermatophyte infections of the body, groin, or feet.

Key Therapeutic Contexts

Terbin is relevant for easing symptoms related to inflammatory or irritative states, such as scaling, redness, and symptoms that create noticeable physiological strain present in widespread ringworm infections. When symptoms may intensify temporarily, the medication provides support that helps ease the overall symptom burden of these distressing skin manifestations and assists with maintaining functional stability. For nail and scalp issues, the therapeutic application contributes to improved comfort during periods of heightened symptoms by assisting with the management of nail dystrophy, which is often characterized by thickening and discoloration. Topical forms are commonly used to address symptoms that interfere with daily functioning in localized surface infections like athlete’s foot, helping to ease peeling and local irritation.

“This application is relevant for easing symptoms of irritation and burning, and supports the patient during difficult episodes by easing distress.”

Quick Fact: Support for Itching and Nail Dystrophy

Eligibility and Restrictions for Use

The eligibility profile for Terbin oral tablets is defined by regulatory guidelines that classify use into established, conditional, and strictly prohibited populations. Use is established for adults who do not have documented contraindications. Eligibility for use by children is conditional, often restricted by minimum age and weight thresholds, with use not recommended for infants due to insufficient clinical data.

Eligibility Classification Population Status
Contraindicated Active or chronic liver disease; Hypersensitivity to Terbinafine; Breastfeeding mothers.
Not Recommended Renal impairment (Creatinine Clearance <50 mL/min); Pregnant women; Children under 2 years old.
Use with Caution Pre-existing Psoriasis or Lupus Erythematosus; Older adults (due to potential for organ impairment).

The most severe restriction is the contraindication for patients with active or chronic liver disease and individuals with a history of allergy to the drug. Use is also contraindicated during lactation due to the medicine’s excretion into breast milk. Use is not recommended for patients with specific levels of renal impairment, as regulatory data has not adequately established safety in this population. These official statements from health authorities dictate who can and cannot use the medicine.

What should I know about interactions with other medicines?

The official interaction profile for Terbin (Terbinafine Hydrochloride) is principally defined by its strong influence on the CYP450 enzyme system and specific patient physiological status.

Interaction-Related Restrictions

The use of oral Terbin is formally contraindicated in two key circumstances: individuals with a known history of allergic reaction to oral terbinafine and patients with active or chronic liver disease. This prohibition regarding liver status reflects a heightened interaction and safety concern within that specific patient population.

Pharmacokinetic Interactions

Terbinafine is classified as a potent inhibitor of the CYP450 2D6 isozyme. This official interaction mechanism may result in significantly increased plasma concentrations of co-administered medicinal products metabolized predominantly by CYP2D6, including certain antidepressants, beta-blockers, and antiarrhythmics, such as Desipramine.

The systemic exposure of Terbinafine itself is altered by co-administered drugs. Cimetidine, an enzyme inhibitor, is documented to cause a substantial increase in Terbinafine exposure. Conversely, Rifampin, an enzyme inducer, causes a significant decrease in Terbinafine systemic exposure.

Administration-Timing and Food

The regulatory information notes a difference in administration timing related to food: the absorption and bioavailability of Terbin tablets are similar regardless of food intake, while the oral granule formulation is formally directed to be taken with soft, nonacidic food.

Mechanism of Action

How Terbin Works: Mechanism of Action

Terbin (Terbinafine) acts through a mechanism that involves critical, dual disruption of the fungal pathogen's essential cellular processes, leading to cell death.


Targeted Blockade of Fungal Sterol Production

The drug's primary action is the non-competitive inhibition of the enzyme Squalene Epoxidase (SQLE), which is essential for the fungal cell to produce Ergosterol, its necessary cell membrane component. This enzyme blockade prevents the synthesis of the fungal cell's necessary structural components.


Mechanism of Toxic Cell Destruction

The blockade of Squalene Epoxidase triggers a mechanistic cascade: not only does the membrane lack essential Ergosterol, but the precursor substance, squalene, accumulates to toxic levels inside the fungal cell. This dual failure—membrane structural compromise and internal poisoning—induces fungal cell lysis (death).


Concentrated Delivery to Infection Sites

The mechanism relies on the drug's physiochemical property to partition and persist in high concentrations within keratinous tissues, such as the outer skin layer, nails, and hair. This tissue selectivity results in a high, sustained concentration of the molecule where the fungal pathogens reside, contributing to a prolonged fungicidal effect.

Dosage and Administration Information

How to Use Terbinafine (Oral): Administration Guidelines

This information describes the parameters for the use of oral Terbinafine (tablets and granules). This section is intended to summarize the requirements for administration and should not be used as clinical advice.


Dosing and Frequency

The approved route of administration for systemic Terbinafine is Oral (by mouth). The standard dose for most adults is 250 mg once daily. Pediatric dosing, particularly for oral granules, is weight-based, with dosages ranging from 125 mg to 250 mg once daily, based on the child's body weight (typically for children 4 years of age).


Administration Conditions

Formulation Timing in Relation to Meals Preparation Requirements
Tablets May be taken with or without food. Swallow whole with water.
Oral Granules Must be taken with food. Sprinkle onto a spoonful of soft, non-acidic food (e.g., pudding). Do not use fruit juices or fruit-based foods.

Granules must be swallowed whole without chewing the food mixture. If a dose is missed, it is advised to take it as soon as remembered unless it is close to the next scheduled dose, in which case the missed dose should be skipped; do not double the dose.


Course Duration

The total treatment duration is fixed and determined by the site of infection. For fingernail onychomycosis, the usual course is 6 weeks. For toenail onychomycosis, the usual course is 12 weeks. This full duration must be completed regardless of when visible improvement occurs.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Terbin

The research evidence for Terbinafine (the active ingredient in Terbin) is based primarily on randomized controlled trials (RCTs), systematic reviews, and long-term observational studies. These studies were designed to observe outcomes in the presence of various fungal infections, mainly those caused by dermatophytes. The findings describe group patterns of clearance and symptom evolution under specific research conditions.


Evidence for Fungal Nail Infections (Onychomycosis)

Pivotal research was conducted using large-scale, controlled trials, primarily involving healthy adults with dermatophyte infections of the toenails. Researchers monitored two main outcomes over long periods: mycological cure (confirming the fungus was no longer present) and clinical cure (assessing the appearance of the nail).

Findings describe that continuous oral Terbinafine was studied for measured mycological clearance at follow-up points. These studies monitored the proportion of unaffected nail area and tracked changes in nail status over time. Available evidence suggests long-term outcomes are not fully established for every patient, as recurrence after the documented clearance was observed in some studies.


Evidence for Scalp Ringworm (Tinea Capitis)

The research examined oral Terbinafine in trials that included comparisons against other oral antifungal agents. The study populations predominantly consisted of children (pediatric patients). Studies explored the outcomes related to both the clearance of the fungus and the outcomes linked to inflammatory or irritative states, such as scaling and redness.

Studies reported how symptoms evolved in the observed populations across defined, short treatment intervals. Evidence suggests that the measured outcomes may vary depending on the specific type of fungus causing the infection.


What Research is Still Needed (Evidence Gaps)

Long-term effects are not fully established for all indications, and there is limited information regarding the durability of cure for skin infections over several years. Data are still emerging for certain non-dermatophyte fungal infections. Studies documented outcomes that varied by the type of fungus, which indicates an area requiring further research. Research is ongoing to better understand outcomes in patients with multiple underlying health conditions.

Frequently Asked Questions (FAQ)

Common questions about Terbin (FAQ)

Q: Does Terbin treat infections other than nail and foot fungus?

According to official product information, oral Terbin tablets are mainly used to treat fungal nail infections and tinea capitis, which is scalp ringworm. However, topical forms of Terbin (creams or solutions) are indicated for localized skin infections like ringworm of the body (tinea corporis), jock itch (tinea cruris), and athlete’s foot.

Q: Can Terbin be used safely by people with pre-existing kidney issues?

Official product information indicates that oral Terbin is generally not recommended for people who have significant pre-existing kidney impairment. This is because there is not enough study data available to establish safety for this specific population.

Q: Is Terbin appropriate for use by older adult patients?

Studies have not reported significant age-dependent changes in how Terbin concentrations appear in the blood of older adults. However, official guidance advises that caution should be used when prescribing Terbin to older patients. This is due to the increased possibility of underlying kidney, liver, or heart issues that may necessitate careful consideration.

Q: Are there known interactions between Terbin and common antidepressant medications?

Terbin is known to be a strong inhibitor of the CYP2D6 enzyme, a protein in the body that processes certain drugs. This interaction can cause a significant increase in the concentration of other medicines in your blood that are processed by the same enzyme. This affected group includes certain antidepressants, such as Desipramine.

Q: Does Terbin interact with common blood pressure medications like beta-blockers?

Official documents describe that Terbin can increase the systemic concentration of other medications that are metabolized by the CYP2D6 enzyme system. Because certain blood pressure medicines, specifically some beta-blockers, are processed by this same enzyme, their levels in the body may increase while taking Terbin.

Q: Can Terbin be safely used by children for fungal infections?

Oral Terbin is approved for treating tinea capitis (scalp ringworm) in children who are 4 years of age or older. Official dosing for children is based on body weight. Due to a lack of sufficient clinical study data, use in children under 4 years old is typically not recommended.

Q: Is Terbin safe to take while a woman is breastfeeding?

Regulatory documents state that Terbin is formally contraindicated for use by women who are breastfeeding. This restriction is based on the fact that the active ingredient is excreted into human breast milk.

Q: What are the restrictions on using Terbin for people with an autoimmune disease like lupus?

Official safety information indicates that cases of cutaneous (skin-related) and systemic lupus erythematosus (Lupus) have been reported in patients taking Terbin. If signs or symptoms of Lupus develop or worsen during treatment, regulatory guidance advises that the medication be discontinued.

Q: Are there any known issues when combining Terbin with certain stomach acid reducers?

Yes, regulatory data documents that combining Terbin with the stomach acid reducer Cimetidine can cause a substantial increase in the concentration of Terbin in the body. Cimetidine is classified as an enzyme inhibitor, which slows down the processing of Terbin.

Q: Is Terbin effective against all types of fungus that cause skin and nail infections?

Terbin is primarily effective against a group of fungi called dermatophytes, which are the most common cause of nail and skin infections. Official microbiology data indicates that its activity against other types of fungi, such as yeasts and non-dermatophytes, can vary. Against those organisms, the drug may only inhibit growth (fungistatic) rather than kill the fungus (fungicidal).

Q: Why is a longer course of treatment sometimes needed for certain patients with toenail infections?

The long treatment duration, typically 12 weeks for toenail infections, is required due to the physical nature of nail growth. The drug must reach high concentrations in the nail bed and persist in the new, growing nail plate over many months. This ensures the entire infected section of the nail is replaced by healthy nail tissue that is free of fungus.

Q: What is the main difference between the Terbin tablet and the topical cream?

The fundamental difference is the site of action. Oral Terbin tablets are used for systemic treatment, meaning they work throughout the body to treat deep or widespread infections, such as those in the nails. Topical creams and solutions, however, are used for localized skin infections like athlete’s foot or ringworm, where the medication is applied directly to the surface.

Q: How does Terbin work to stay in the nail for a long time?

Regulatory information on the drug’s properties indicates that Terbin is highly attracted to fat and oil (lipophilic). This characteristic causes it to rapidly accumulate in keratinous tissues, which include the skin, hair, and nails. This accumulation allows the antifungal concentrations to persist at the site of infection for several weeks or months even after the medicine has been stopped.

Q: How soon after starting the tablets should someone expect to see improvement?

Because Terbin treats nail infections by targeting the fungus in the nail bed and allowing a healthy nail to grow out, visible improvement takes time. Visible improvements may be observed after several weeks to months after starting the tablets before a noticeable change in the appearance of the infected nail occurs.

Q: Why does Terbin treatment for toenails usually take several months?

The standard treatment duration for toenail infections is fixed at 12 weeks. This length of time is necessary to ensure the medication saturates the nail bed and persists throughout the entire period required for the slow-growing toenail to be fully replaced by new, uninfected growth.

Q: Does Terbin continue to work in the body after the last dose is taken?

Yes, studies show that Terbin continues to work after the last dose is taken. Due to its property of concentrating in the keratinous tissues of the skin and nails, the drug maintains effective antifungal levels. This persistence helps to prevent the recurrence of the infection for up to three months after treatment cessation.

Q: What is the risk of experiencing liver problems while taking Terbin?

Official data indicates that severe liver injury is a rare adverse event, estimated to occur in a small fraction of prescriptions. Despite the rarity, the outcomes can be serious, sometimes requiring a liver transplant or resulting in death. Regulatory guidance recommends monitoring for this reason.

Q: What signs or symptoms of liver issues should a patient look for while on Terbin?

Patients should be aware of certain clinical signs that may suggest a liver issue. These include persistent or unexplained nausea and vomiting, the appearance of dark urine or pale stools, pain in the upper right abdomen, and jaundice, which is the yellowing of the skin or eyes. If any of these signs develop, regulatory information advises consulting a healthcare provider, as the medicine may need to be stopped.

Q: Is regular blood testing required for all patients taking Terbin tablets?

Official regulatory guidelines recommend liver function monitoring for patients taking oral Terbin. Monitoring is suggested before starting treatment and periodically throughout the course. This is done to detect any changes in liver function early, and discontinuation is advised if signs of liver injury are observed.

Q: What are the most common non-serious side effects associated with Terbin?

The most frequently reported non-serious side effects are classified as very common or common in official documents. These include headache and gastrointestinal issues like diarrhea, nausea, stomach pain, or dyspepsia (indigestion). Other common effects are rash, itching (pruritus), and temporary elevations of liver enzymes.

Q: Is a loss or change of taste a temporary side effect of Terbin?

Changes or loss of taste (dysgeusia/ageusia) are documented side effects of Terbin. While this side effect often resolves within a few weeks after stopping the medication, the official product label states that the disturbance may be prolonged or permanent in rare instances.

Q: How long after stopping the medication does the sense of taste typically return?

When taste or smell disturbances do occur and are temporary, they typically begin to resolve within a few weeks after the medication course is completed.

Q: Can taking Terbin make the skin more sensitive to sunlight?

Yes, photosensitivity reactions are documented as rare side effects in official safety reports. This means the skin may react more strongly to sunlight. It is important that precautions be taken to protect the skin from sun exposure.

Q: Is there a link between taking Terbin and changes in mood, such as depressive feelings?

Depression and anxiety are documented psychiatric side effects reported in postmarketing experience. Official guidance suggests that any feelings of depression or anxiety that occur during the course of treatment be reported.

Q: Does Terbin interact with common pain relievers like ibuprofen or paracetamol?

Regulatory information indicates that Terbin tablets can generally be taken alongside common over-the-counter pain relievers like paracetamol (acetaminophen) and ibuprofen. However, due to its effect on the CYP2D6 enzyme, Terbin can affect the way the body processes certain opioid-based pain relievers, such as tramadol or codeine.

Q: Can Terbin affect the effectiveness of oral birth control pills?

Laboratory studies conducted outside the body have shown that Terbin does not inhibit the metabolism of ethinylestradiol, a component commonly found in oral birth control pills. However, consultation with a healthcare provider regarding the use of Terbin with a specific contraception method is advised.

Q: Is it necessary to avoid alcohol completely while undergoing Terbin treatment?

Due to the known rare risk of liver injury associated with Terbin, it is generally advised that alcohol consumption be limited or avoided during treatment. This recommendation is based on the fact that alcohol consumption can also place additional stress on the liver.

Q: Does consuming caffeine interfere with how Terbin works?

Yes, drug-interaction studies have shown that Terbin decreases the speed at which caffeine is cleared from the body by approximately 19%. This interaction means that taking Terbin can increase the concentration of caffeine in the body.

Q: Are there any drug classes that have significant interactions with Terbin?

Yes, Terbin is a potent inhibitor of the CYP450 2D6 enzyme system. This means it has the potential to significantly increase the concentration of medicines that are predominantly processed by this pathway. Drug classes affected include certain beta-blockers, antiarrhythmics, and some antidepressants.

Q: How is Terbin eliminated from the body?

Official pharmacokinetic data indicates that Terbin is extensively processed by the body. Approximately 70% of the administered dose is then eliminated from the body through the urine, primarily in the form of inactive compounds (metabolites).

Q: Can Terbin cause a rash that is not a sign of a serious reaction?

Yes, the official safety profile lists rash and itching (pruritus) as very common to common side effects. However, a progressive or severe rash is a reason to consult a healthcare provider, as the medication may need to be discontinued.

Q: Why is it important to complete the full course of Terbin even if symptoms improve quickly?

Regulatory documents emphasize that the full course of therapy must be completed, even if the symptoms appear to improve early. This is necessary to ensure the fungal pathogen is completely eradicated from the deep tissue. Stopping treatment early may increase the likelihood that the infection will recur or that the fungus may develop resistance to the medication.

Q: What should be done if symptoms seem to worsen after starting Terbin?

Official guidance suggests that any lack of improvement or worsening of symptoms be discussed with a healthcare provider.

Q: Are there any dietary restrictions other than alcohol that should be considered with Terbin?

For the oral granule formulation, regulatory guidelines specify that the granules must be mixed with soft, non-acidic foods, such as mashed potatoes or pudding. Fruit juices or fruit-based foods are advised against. No other general food restrictions are specified for the tablet formulation.

Q: Does Terbin treatment cause hair loss in some patients?

Hair loss, medically termed alopecia, is listed in official documentation as a very rare side effect. This has been reported in postmarketing experience.

Q: Can Terbin cause problems with vision or eyesight?

Official safety reports include visual disturbances as a documented postmarketing side effect. These reported issues include blurred vision, reduced visual clarity (acuity), and changes in the ocular lens.

How should Terbin be stored and disposed of?

How to Store and Dispose of Terbin?

The storage and disposal of Terbin (Terbinafine Hydrochloride) must adhere strictly to official regulatory guidelines to maintain its stability and ensure safety.

Requirement Official Rule
Temperature Store oral tablets at room temperature (typically below 25 C).
Protection Keep the medicine out of the sight and reach of children and protected from light and moisture.
Container Keep the product in its original container, ensuring it is tightly closed.
Prohibition The medicine must not be frozen.
Disposal Dispose of unused or expired product according to local regulations. Do not flush down a toilet or throw into wastewater.

Following these mandatory storage conditions, defined in regulatory labeling, protects the product from degradation, while adhering to disposal rules ensures environmental safety.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Terbin found in:

A-Z Index: